Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03GES
|
||||
| Former ID |
DNC003872
|
||||
| Drug Name |
1-Benzyl-4-(3-oxazol-5-yl-pyrrol-1-yl)-piperidine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [525629] | ||
| Formula |
C19H21N3O
|
||||
| Canonical SMILES |
C1CN(CCC1N2C=CC(=C2)C3=CN=CO3)CC4=CC=CC=C4
|
||||
| InChI |
1S/C19H21N3O/c1-2-4-16(5-3-1)13-21-9-7-18(8-10-21)22-11-6-17(14-22)19-12-20-15-23-19/h1-6,11-12,14-15,18H,7-10,13H2
|
||||
| InChIKey |
ASGPPKHUWWRTLM-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | D(3) dopamine receptor | Target Info | Inhibitor | [525629] | |
| D(4) dopamine receptor | Target Info | Inhibitor | [525629] | ||
| D(2) dopamine receptor | Target Info | Inhibitor | [525629] | ||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathwayP00026:Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| References | |||||